

# AgustÃ-n Albillos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1979194/publications.pdf>

Version: 2024-02-01

145  
papers

11,375  
citations

31976

53  
h-index

31849

101  
g-index

158  
all docs

158  
docs citations

158  
times ranked

9314  
citing authors

#	ARTICLE	IF	CITATIONS
1	Consenso AEEH «Consenso sobre métodos de detección y derivación de enfermedades hepáticas prevalentes ocultas». Gastroenterología Y Hepatología, 2023, 46, 236-247.	0.5	2
2	Cirrhosis-associated immune dysfunction. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 112-134.	17.8	139
3	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 2276-2286.e6.	4.4	42
4	Congestive Cardiac Hepatopathy. , 2022, , 189-213.		0
5	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	4.1	7
6	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis-Related Cirrhosis. Hepatology Communications, 2022, 6, 1392-1402.	4.3	5
7	Self-expandable metal stent fixation with a temporary Overstitch Apollo; 1/2 suture as a rescue therapy for a reluctant tuberculous esophageal-mediastinal fistula. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	1
8	Nonselective beta-blockers in patients with ascites: The complex interplay among the liver, kidney and heart. Liver International, 2022, 42, 749-761.	3.9	18
9	Reply to: «Potential novel approaches to prevent the risk of infection in patients with variceal bleeding». Journal of Hepatology, 2022, 76, 752-753.	3.7	0
10	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). Gastroenterología Y Hepatología, 2022, 45, 724-734.	0.5	3
11	Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies. Current Oncology, 2022, 29, 2442-2453.	2.2	6
12	Prognostic role of ISR-4 in the survival of patients with pancreatic cancer.. Histology and Histopathology, 2022, , 18432.	0.7	4
13	Over the scope clip (OTSC) as rescue treatment for gastrointestinal bleeding secondary to peptic ulcer disease. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	0
14	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Alimentary Pharmacology and Therapeutics, 2022, 56, 131-143.	3.7	9
15	An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions. Membranes, 2022, 12, 552.	3.0	8
16	Postsurgical bile duct disruption: Digital single-operator cholangioscopy-assisted recanalization. Endoscopy, 2021, 53, 764-765.	1.8	0
17	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 240-248.	2.8	11
18	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology, 2021, 160, 193-205.e10.	1.3	97

#	ARTICLE	IF	CITATIONS
19	Hepatocellular carcinoma after Fontan surgery: A systematic review. <i>Hepatology Research</i> , 2021, 51, 116-134.	3.4	30
20	Massive impact of coronavirus disease 2019 pandemic on gastroenterology and hepatology departments and doctors in Spain. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1627-1633.	2.8	19
21	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
22	Reply to: "Open or closed window: That is the question". <i>Journal of Hepatology</i> , 2021, 74, 486-487.	3.7	0
23	Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. <i>Hepatology Communications</i> , 2021, 5, 309-322.	4.3	13
24	Systemic Inflammation and the Breakdown of Intestinal Homeostasis Are Key Events in Chronic Spinal Cord Injury Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 744.	4.1	18
25	Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 780-786.	0.3	2
26	Expansion of CD4 T Lymphocytes Expressing Interleukin 17 and Tumor Necrosis Factor in Patients with Major Depressive Disorder. <i>Journal of Personalized Medicine</i> , 2021, 11, 220.	2.5	32
27	The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2021, 12, 660179.	4.8	56
28	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e587-e593.	1.6	1
29	The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, S82-S100.	3.7	37
30	"Positron emission tomography for the diagnosis of tipsitis". <i>Digestive and Liver Disease</i> , 2021, 53, 1675-1677.	0.9	0
31	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
32	Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management. <i>Seminars in Liver Disease</i> , 2021, 41, 538-550.	3.6	5
33	A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation. <i>JHEP Reports</i> , 2021, 3, 100291.	4.9	23
34	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36
35	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
36	Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review). <i>Oncology Letters</i> , 2021, 22, 809.	1.8	7

#	ARTICLE	IF	CITATIONS
37	O09â€¦A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5
38	A new single-use disposable duodenoscope (EXALT;½Model D) for the treatment of an anastomotic biliary stenosis in a liver transplant patient. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.3	1
39	Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis. Endoscopy International Open, 2021, 09, E1740-E1751.	1.8	15
40	The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology, 2020, 72, 558-577.	3.7	935
41	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂInfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	4.4	77
42	Development and Validation of Hepamet Fibrosis Scoring Systemâ€“A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	4.4	104
43	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	4.4	74
44	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. Journal of Hepatology, 2020, 72, 702-710.	3.7	45
45	Fontan proteinâ€losing enteropathy is associated with advanced liver disease and a proinflammatory intestinal and systemic state. Liver International, 2020, 40, 638-645.	3.9	22
46	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. Journal of Hepatology, 2020, 72, 885-895.	3.7	107
47	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	4.1	39
48	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
49	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
50	Endoscopy-Related Bleeding and Thromboembolic Events in Patients on Direct Oral Anticoagulants or Vitamin K Antagonists. Clinical Gastroenterology and Hepatology, 2020, , .	4.4	8
51	Letter: improve survival! Place early preâ€emptive TIPSS in highâ€risk variceal bleeders. Alimentary Pharmacology and Therapeutics, 2020, 52, 927-928.	3.7	5
52	Reply to: â€œBeta-blockers in refractory ascites â€ is it truly the end of the road?â€ Journal of Hepatology, 2020, 73, 1291-1292.	3.7	1
53	Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. Clinical Infectious Diseases, 2020, 71, 2726-2729.	5.8	23
54	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. Journal of Infectious Diseases, 2020, 222, 726-733.	4.0	43

#	ARTICLE	IF	CITATIONS
55	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
56	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
57	Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study. <i>Pancreatology</i> , 2020, 20, 331-337.	1.1	11
58	Lumen-apposing metal stents versus biliary fully-covered metal stents for EUS-guided drainage of pancreatic fluid collections: a case control study. <i>Endoscopy International Open</i> , 2020, 08, E6-E12.	1.8	9
59	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
60	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
61	Blunted Expansion of Regulatory T Lymphocytes Is Associated With Increased Bacterial Translocation in Patients With Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 591962.	2.6	25
62	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. <i>Journal of Hepatology</i> , 2020, 73, 1404-1414.	3.7	58
63	Management of pancreatic collections: an update. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 483-490.	0.3	4
64	OUTCOMES OF DRUG-INDUCED ACUTE PANCREATITIS: A TEN-YEAR EXPERIENCE OF AN ACADEMIC CENTER. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 113, 276-279.	0.3	4
65	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
66	Sepsis in Patients With Cirrhosis Awaiting Liver Transplantation: New Trends and Management. <i>Liver Transplantation</i> , 2019, 25, 1700-1709.	2.4	6
67	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. <i>Journal of Hepatology</i> , 2019, 71, 942-950.	3.7	61
68	FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. <i>Journal of Hepatology</i> , 2019, 71, 1126-1140.	3.7	153
69	Biliary sphincterotomy reduces the risk of acute gallstone pancreatitis recurrence in non-candidates for cholecystectomy. <i>Digestive and Liver Disease</i> , 2019, 51, 1567-1573.	0.9	12
70	Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 581-590.e6.	1.0	35
71	Hepatic angiosarcoma in a patient with liver cirrhosis. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 304-305.	0.5	2
72	Genetic and flow cytometry analysis of seronegative celiac disease: a cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 563-570.	1.5	10

#	ARTICLE	IF	CITATIONS
73	Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango. <i>Frontiers in Immunology</i> , 2019, 10, 973.	4.8	60
74	Characteristics and consequences of missed gastric cancer: A multicentric cohort study. <i>Digestive and Liver Disease</i> , 2019, 51, 894-900.	0.9	21
75	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	13.7	375
76	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. <i>Hepatology</i> , 2019, 70, 911-924.	7.3	11
77	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	4.8	134
78	Reply. <i>Hepatology</i> , 2019, 69, 2306-2307.	7.3	0
79	Abnormal Distribution and Function of Circulating Monocytes and Enhanced Bacterial Translocation in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2019, 10, 812.	2.6	53
80	Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. <i>United European Gastroenterology Journal</i> , 2019, 7, 189-198.	3.8	46
81	Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis. <i>Hepatology</i> , 2019, 70, 925-938.	7.3	70
82	Pólipo de Nakamura: un hallazgo endoscópico infrecuente. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 34-35.	0.5	2
83	Trasplante de precursores hematopoyéticos en enfermedad de Crohn refractaria: experiencia en nuestro centro. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 16-22.	0.5	3
84	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	3.7	225
85	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	7.3	80
86	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019, 42, 579-592.	0.5	25
87	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.5	12
88	Clinical validation of Endofasteri <sup>®</sup> for a rapid diagnosis of <i>Helicobacter pylori</i> infection. <i>Revista Española De Enfermedades Digestivas</i> , 2019, 112, 23-26.	0.3	6
89	A multicentric Spanish study on the characteristics and survival of gastric adenocarcinoma under the age of 60. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 595-603.	0.5	4
90	Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: focus on treatment intensity. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 1756284819879565.	3.2	6

#	ARTICLE	IF	CITATIONS
91	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterología Y Hepatología, 2018, 41, 328-349.	0.5	71
92	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	1.3	162
93	Fontan-associated Liver Disease. Revista Espanola De Cardiologia (English Ed ), 2018, 71, 192-202.	0.6	12
94	Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease, 2018, 50, 1345-1350.	0.9	4
95	Incidence, predictive factors and impacts of acute kidney injury in cirrhotic patients hospitalized for cellulitis. Liver International, 2018, 38, 285-294.	3.9	7
96	Fontan-Associated Liver Disease: A Review. Annals of Hepatology, 2018, 17, 192-204.	1.5	65
97	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Espanola De Enfermedades Digestivas, 2018, 110, 641-649.	0.3	3
98	Experiencia en práctica clínica de optimización de tiopurinas mediante determinación de sus metabolitos en la enfermedad inflamatoria intestinal. Gastroenterología Y Hepatología, 2018, 41, 629-635.	0.5	7
99	Risk stratification and treatment of primary biliary cholangitis. Revista Espanola De Enfermedades Digestivas, 2018, 111, 63-70.	0.3	1
100	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology, 2017, 65, 1810-1822.	7.3	78
101	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of Hepatology, 2017, 66, 1138-1148.	3.7	159
102	Targeting the gut-liver axis in liver disease. Journal of Hepatology, 2017, 67, 1084-1103.	3.7	311
103	Sepsis in alcohol-related liver disease. Journal of Hepatology, 2017, 67, 1031-1050.	3.7	93
104	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology, 2017, 66, 1219-1231.	7.3	80
105	Do patients with iron deficiency without anemia benefit from an endoscopic examination?. Journal of Digestive Diseases, 2017, 18, 416-424.	1.5	6
106	Acute variceal bleeding in patients on primary prophylaxis with nonselective beta-blockers: A poor prognosis factor?. Hepatology, 2017, 65, 1774-1774.	7.3	0
107	Effects of All-Oral Anti-Viral Therapy on HVPC and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology, 2017, 153, 1273-1283.e1.	1.3	210
108	Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. Gastroenterología Y Hepatología, 2017, 40, 538-580.	0.5	20

#	ARTICLE	IF	CITATIONS
109	The endoscopic ultrasound-assisted Rendez-Vous technique for treatment of recurrent pancreatitis due to pancreas divisum and ansa pancreatica. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017, 109, 798-800.	0.3	6
110	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , 2016, 64, 224-231.	7.3	69
111	Continued controversy over the safety of beta-blockers in decompensated cirrhosis. <i>Hepatology</i> , 2016, 63, 1726-1729.	7.3	3
112	Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
113	Reply. <i>Gastroenterology</i> , 2016, 151, 761-762.	1.3	0
114	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
115	Prognostic value of bacterial infection in acute and chronic liver failure. <i>Liver International</i> , 2016, 36, 1090-1092.	3.9	4
116	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
117	Evaluation of the short- and long-term effectiveness and safety of fully covered self-expandable metal stents for drainage of pancreatic fluid collections: results of a Spanish nationwide registry. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 450-457.e2.	1.0	81
118	Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. <i>Journal of Hepatology</i> , 2016, 64, 1049-1057.	3.7	139
119	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
120	Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. <i>Liver International</i> , 2015, 35, 2009-2016.	3.9	65
121	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.4	25
122	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
123	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	3.7	685
124	Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. <i>Journal of Hepatology</i> , 2014, 61, 1385-1396.	3.7	870
125	Secondary Prophylaxis for Esophageal Variceal Bleeding. <i>Clinics in Liver Disease</i> , 2014, 18, 359-370.	2.1	20
126	Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 723-730.	3.7	51



#	ARTICLE	IF	CITATIONS
127	Systemic inflammation in absence of gut bacterial translocation in C57BL/6 mice with cirrhosis. <i>Gut</i> , 2013, 62, 330-331.	12.1	4
128	The window hypothesis: haemodynamic and non-haemodynamic effects of $\beta_2$ -blockers improve survival of patients with cirrhosis during a window in the disease: Figure 1. <i>Gut</i> , 2012, 61, 967-969.	12.1	180
129	Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. <i>Hepatology</i> , 2012, 56, 1861-1869.	7.3	56
130	Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. <i>Hepatology</i> , 2010, 52, 2086-2095.	7.3	41
131	The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis. <i>Gut</i> , 2010, 59, 943-952.	12.1	9
132	Role of Endoscopy in Primary Prophylaxis for Esophageal Variceal Bleeding. <i>Clinics in Liver Disease</i> , 2010, 14, 231-250.	2.1	5
133	Meta-analysis: Combination Endoscopic and Drug Therapy to Prevent Variceal Rebleeding in Cirrhosis. <i>Annals of Internal Medicine</i> , 2008, 149, 109.	3.9	169
134	Value of the Hepatic Venous Pressure Gradient to Monitor Drug Therapy for Portal Hypertension: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2007, 102, 1116-1126.	0.4	137
135	The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. <i>Gut</i> , 2007, 56, 259-264.	12.1	24
136	Preventing First Variceal Hemorrhage in Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S305-S311.	2.2	28
137	Mesenteric Th1 polarization and monocyte TNF- $\alpha$ production: First steps to systemic inflammation in rats with cirrhosis. <i>Hepatology</i> , 2005, 42, 411-419.	7.3	62
138	A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. <i>Journal of Hepatology</i> , 2005, 43, 990-996.	3.7	151
139	Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. <i>Journal of Hepatology</i> , 2004, 40, 624-631.	3.7	128
140	Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. <i>Lancet</i> , The, 2004, 363, 1608-1610.	13.7	93
141	Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. <i>Hepatology</i> , 2003, 37, 208-217.	7.3	381
142	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	121
143	Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. <i>Hepatology</i> , 2000, 31, 43-48.	7.3	228
144	Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study. <i>Hepatology</i> , 2000, 32, 471-476.	7.3	196

#	ARTICLE	IF	CITATIONS
145	Increased spontaneous and lymphokine-conditioned IgA and IgG synthesis by B cells from alcoholic cirrhotic patients. <i>Hepatology</i> , 1992, 16, 664-670.	7.3	38